Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Suneetha B, Thomas"'
Autor:
Jill Walker, Jane Osbourn, Arnaud C. Tiberghien, Nazzareno Dimasi, Dipesha P. Shah, Terrence O'Day, Steven Novick, William O. Iverson, Yuling Wu, Bo Zheng, Shannon Breen, Subramanya Karanth, Ryan Fleming, Agnieszka Sadowska, Christopher Ward, Vanessa Muniz-Medina, Suneetha B. Thomas, Elaine M. Hurt, Michael G. Overstreet, Saravanan Rajan, Ruoyan Chen
Multiple myeloma is a hematologic cancer that disrupts normal bone marrow function and has multiple lines of therapeutic options, but is incurable as patients ultimately relapse. We developed a novel antibody–drug conjugate (ADC) targeting CS-1, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::063a7b8839eda8429b31260763a0368a
https://doi.org/10.1158/1535-7163.c.6542664
https://doi.org/10.1158/1535-7163.c.6542664
Autor:
Jill Walker, Jane Osbourn, Arnaud C. Tiberghien, Nazzareno Dimasi, Dipesha P. Shah, Terrence O'Day, Steven Novick, William O. Iverson, Yuling Wu, Bo Zheng, Shannon Breen, Subramanya Karanth, Ryan Fleming, Agnieszka Sadowska, Christopher Ward, Vanessa Muniz-Medina, Suneetha B. Thomas, Elaine M. Hurt, Michael G. Overstreet, Saravanan Rajan, Ruoyan Chen
Supplementary Materials and Methods, Supplementary Table S1. Sources of cell lines and cell growth media; Supplemental Table S2. Sources of antibodies for flow cytometry; Supplementary Table S3. CS-1 ADC Characteristics, Supplemental Table S4. Pharma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62318dd34971780d373a1e55ed154426
https://doi.org/10.1158/1535-7163.22520520.v1
https://doi.org/10.1158/1535-7163.22520520.v1
Autor:
Stephen Blackmore, Kathy Mulgrew, Fiona Cusdin, Suneetha B. Thomas, Elaine M. Hurt, Claire Dobson, Emily Brannigan, James Moynihan, Roger Bradley Dodd, Anna Gudny Sigurdardottir, Rajesh Kumar, Peter Cariuk, Mark Cobbold
Publikováno v:
Cancer Research. 81:1828-1828
Immunotherapy has revolutionized patient care, however, the majority of patients with cancer still do not benefit from this treatment modality. This is due to many factors, including a complex tumor microenvironment (TME) that has too few functional
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b6282b0600acdfc6128132eb0b11a028
https://doi.org/10.1158/1538-7445.am2021-1828
https://doi.org/10.1158/1538-7445.am2021-1828
Autor:
Bo Zheng, Dipesha P. Shah, Jill Walker, Subramanya Karanth, William O. Iverson, Vanessa Muniz-Medina, Yuling Wu, Ruoyan Chen, Nazzareno Dimasi, Jane Osbourn, Arnaud C. Tiberghien, Suneetha B. Thomas, Saravanan Rajan, Elaine M. Hurt, Shannon Breen, Ryan Fleming, Agnieszka Sadowska, Michael G. Overstreet, Christopher Ward, Terrence O'Day, Steven Novick
Publikováno v:
Molecular cancer therapeutics. 19(8)
Multiple myeloma is a hematologic cancer that disrupts normal bone marrow function and has multiple lines of therapeutic options, but is incurable as patients ultimately relapse. We developed a novel antibody–drug conjugate (ADC) targeting CS-1, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d24820dd9755e2b004133692d71eb38f
https://pubmed.ncbi.nlm.nih.gov/32404408
https://pubmed.ncbi.nlm.nih.gov/32404408
Autor:
Krista, Kinneer, Matt, Flynn, Suneetha B, Thomas, John, Meekin, Reena, Varkey, Xiaodong, Xiao, Haihong, Zhong, Shannon, Breen, Paul G, Hynes, Ryan, Fleming, Binyam, Bezabeh, Cui Tracy, Chen, Leslie, Wetzel, Ruoyan, Chen, Nazzareno, Dimasi, Yu-Tzu, Tai, Kenneth C, Anderson, Ronald, Herbst, Philip W, Howard, Elaine M, Hurt, David A, Tice
Publikováno v:
Leukemia. 33(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f3af39c8da80648fa1a5430a990fa445
https://pubmed.ncbi.nlm.nih.gov/30315237
https://pubmed.ncbi.nlm.nih.gov/30315237
Autor:
Lesley A. Mathews, Stephanie M. Cabarcas, Lei Sun, William L. Farrar, Suneetha B. Thomas, Xiaohu Zhang
Publikováno v:
Pancreas. 42:861-870
Objective Pancreatic cancer is a leading cancer type and its molecular pathology is poorly understood. The only potentially curative therapeutic option available is complete surgical resection; however, this is inadequate as most of the patients are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94ef31c250a4fbe063a7a70d41acbc98
https://doi.org/10.1097/mpa.0b013e318279d568
https://doi.org/10.1097/mpa.0b013e318279d568
Autor:
Elaine M. Hurt, James Cherry, Stephanie M. Cabarcas, Eric Lader, Xiaohu Zhang, Thomas Sebastian, William L. Farrar, Subu Yerramilli, Suneetha B. Thomas
Publikováno v:
Genomics. 99(2):108-117
TICs are characterized by their ability to self-renew, differentiate and initiate tumor formation. miRNAs are small noncoding RNAs that bind to mRNAs resulting in regulation of gene expression and biological functions. The role of miRNAs and TICs in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2053e43868391a4a006f9d3d36935249
Autor:
William L. Farrar, King C. Chan, Maria A. Duhagon Serrat, Elaine M. Hurt, Timothy D. Veenstra, Suneetha B. Thomas
Publikováno v:
Stem Cells. 28:390-398
There is mounting evidence that tumors are initiated by a rare subset of cells called cancer stem cells (CSCs). CSCs are generally quiescent, self-renew, form tumors at low numbers, and give rise to the heterogeneous cell types found within a tumor.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1127f1b18953e1c78e26559cc7635c36
https://doi.org/10.1002/stem.271
https://doi.org/10.1002/stem.271
Molecular consequences of SOD2 expression in epigenetically silenced pancreatic carcinoma cell lines
Publikováno v:
British Journal of Cancer
Manganese superoxide dismutase (SOD2) is an enzyme that catalyses the dismutation of superoxide in the mitochondria, leading to reduced levels of reactive oxygen species. Reduced expression levels of SOD2 have been shown to result in increased DNA da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdb6f70da8fe79cc17603154aa739b09
http://europepmc.org/articles/PMC2360443
http://europepmc.org/articles/PMC2360443
Publikováno v:
Cancer Biology & Therapy. 5:1154-1160
Inactivation of the p53 pathway is a common feature of neoplasia. Dysregulation of the p53 pathway has been shown to involve mutations of p53, increased expression of the p53 inhibitor HDM-2, or epigenetic silencing of the p53 promoter. In multiple m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b687c6fcd31d74c9577a27c712a2318
https://doi.org/10.4161/cbt.5.9.3001
https://doi.org/10.4161/cbt.5.9.3001